Compound 5g produced stronger cytotoxic effects than paclitaxel against AGS and HT-29 cells in the reported assays. Doxorubicin, included as a reference drug, remained the most potent treatment across all four cell lines. Compounds 5d, 5f and 5h each had an IC₅₀ above 600 µM in NIH3T3 cells and showed selective activity against some of the cancer cell lines. The abstract does not provide the complete numerical results for each compound and cell-line comparison, nor does it establish whether the observed differences were statistically significant.

The investigators also conducted molecular docking and molecular dynamics analyses to examine the modeled interaction of the synthesized compounds with tubulin. Docking predicted that all compounds would bind within tubulin’s colchicine-binding site with more favorable scores than combretastatin A-4. These are computational predictions rather than experimental confirmation of binding. The molecular dynamics analysis indicated that the modeled complex containing compound 5i was more stable than the compound 5d complex.

Together, the cell-based measurements and computational models identified compound 5g as a potential tubulin inhibitor for further study, but the findings remain preclinical. The research was limited to four cultured cell lines and computer modeling; no animal or human clinical evaluation was reported in the abstract. The authors stated that additional experimental and in vivo validation would be required, and the results do not demonstrate anticancer benefit in patients.

Subject of Research: Preclinical evaluation of 1,2,3-thiadiazole derivatives in cancer cell assays and molecular modeling

Article Title: Design, synthesis, and biological evaluation of novel 4,5-diaryl-1,2,3-thiadiazole derivatives: anticancer activity and molecular docking studies

Article References: Ghasemi, M., Ghadbeigi, S., Ostad, S. N., Kalhor, H., & Amini, M. (2026). Design, synthesis, and biological evaluation of novel 4,5-diaryl-1,2,3-thiadiazole derivatives: anticancer activity and molecular docking studies. Scientific Reports. https://doi.org/10.1038/s41598-026-72795-2

Image Credits: AI Generated

DOI: 10.1038/s41598-026-72795-2

Keywords: 1,2,3-thiadiazoles, anticancer screening, cell cultures, cytotoxicity, MTT assay, molecular docking, molecular dynamics, tubulin, compound 5g, preclinical research, Design, synthesis

The researchers examined antioxidant activity using DPPH, hydrogen peroxide, superoxide dismutase and ABTS assays. The essential oil produced pronounced scavenging activity across all four tests, according to the study summary. Because the available report does not provide assay-specific numerical results, it does not allow direct comparison of the magnitude of activity among the four methods or calculation of an overall effect size.

The summary also does not report the detailed chemical composition of the tested oil, limiting attribution of the measured effects to particular constituents. The cancer-cell experiment used KB, a human oral carcinoma cell line. MTT testing covered concentrations ranging from 6.25 to 100 µg/mL, a 16-fold span between the lowest and highest doses.

The reported IC50 was 22.8 µg/mL, while viability declined as the oil concentration increased. The investigators described this pattern as significant, concentration-dependent cytotoxicity and considerable antiproliferative activity. Their separate membrane-damage assessment also indicated an effect on KB cells, although the supplied summary does not identify the procedure or provide quantitative membrane results.

The authors proposed that the oil’s many bioactive components, including functional groups associated with free-radical scavenging and inhibition of cancer cells, may account for the observed activity. The results therefore support further investigation of Piper betle leaf essential oil as a material with laboratory-measured antioxidant and cytotoxic activity, not a conclusion that it acts as a therapeutic anticancer agent. This was a laboratory study conducted in vitro, with testing in chemical assay systems and one cultured human cancer cell line.

It did not evaluate treatment of cancer in animals or humans, and the supplied evidence does not establish effects on normal cells, selectivity between cancer and non-cancerous cells, absorption, dosing, safety, efficacy or clinical benefit. No basis is provided for recommending ingestion, inhalation or topical use of the essential oil. Taken together, the findings offer a preliminary experimental signal across four free-radical-scavenging assays and KB-cell viability and membrane assessments, while questions about composition, mechanism, selectivity and translation to living organisms remain unresolved.

Subject of Research: In vitro antioxidant and cytotoxic testing of Piper betle leaf essential oil

Article Title: In vitro assessment of the free radical scavenging and cytotoxic activities of Piper betle leaf essential oil

Article References: Janani, P., Anju, A., Anjana, A., Babu, R. D., & Meiyalagan, V. (2026). In vitro assessment of the free radical scavenging and cytotoxic activities of Piper betle leaf essential oil. Medical Oncology, 43(11), Article 336. https://doi.org/10.1007/s12032-026-03462-9

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03462-9

Keywords: Piper betle, leaf essential oil, free-radical scavenging, antioxidant assays, oral carcinoma, KB cells, cell viability, cytotoxicity, MTT assay, in vitro research, vitro, assessment

The 1,3,4-oxadiazole ring is a five-membered heterocycle comprising one oxygen and two nitrogen atoms, widely investigated in medicinal chemistry for its aromatic stability and bioisosterism with the carbonyl group in amides and esters. Heterocyclic scaffolds make up more than 85 percent of FDA-approved drug molecules, owing to their ability to form various intermolecular interactions including hydrogen bonding, metal coordination, π–π stacking, hydrophobic interactions, and van der Waals contacts. Several biological activities have been reported for 1,3,4-oxadiazoles, including antimicrobial, anti-inflammatory, antioxidant, and anticancer effects, with reported anticancer mechanisms including inhibition of growth factor receptors such as EGFR and VEGFR and induction of apoptosis in several tumor types. However, oxadiazole-based compounds had not previously been explored specifically for oligodendroglioma.

The synthesis proceeded through acid-catalyzed condensation of the appropriate hydrazides with aromatic aldehydes in absolute ethanol under reflux to afford hydrazone intermediates, which were then oxidatively cyclized using iodine and potassium carbonate in dimethyl sulfoxide at 100 °C for three to six hours to yield the final oxadiazole derivatives. Seven compounds were produced, designated A1 through A3 and B1 through B4, with the A series bearing a 5-chloro-2-nitrophenyl substituent and the B series bearing a 4-cyanophenyl substituent at the C-5 position of the oxadiazole ring. Characterization was carried out by FT-IR, proton NMR, carbon-13 NMR, and electron ionization mass spectrometry, with the infrared spectra supporting complete ring closure by the disappearance of the N–H stretching band and the amide carbonyl C=O stretching band of the hydrazones, alongside the appearance of characteristic C=N stretching of the oxadiazole ring and C–O–C asymmetric stretching.

Biological evaluation used the MTT colorimetric assay, which is based on the reduction of a yellow tetrazolium salt by mitochondrial dehydrogenase enzymes in metabolically active cells, producing an insoluble purple formazan product whose absorbance correlates directly with cell viability. Cells were plated at 10,000 cells per well in 96-well microplates, incubated for 24 hours, and exposed to serial concentrations of the test compounds ranging from 10 to 1,000 µg/mL, with cisplatin run in parallel as a reference drug. The IC50 values of all seven compounds were lower than that of cisplatin, which recorded an IC50 of 212.27 µg/mL against HS683 cells. Compounds bearing the 4-cyanophenyl group at C-5 were consistently more active than their A analogs, with IC50 values approximately half those of the matched pairs.

The selectivity index, calculated as the ratio of the IC50 against normal human astrocytes to the IC50 against HS683 cells, showed a clear advantage of the synthesized compounds over cisplatin, whose SI of 1.25 indicates near-equal toxicity toward tumor and normal cells. All seven compounds gave SI values greater than 1, with B2 achieving the highest SI of 14.55, followed by A2 with an SI exceeding 12.15, whose IC50 against normal human astrocytes exceeded 1,000 µg/mL, indicating minimal toxicity toward healthy brain cells. This favorable selectivity profile is particularly significant given that treatment-related adverse effects remain difficult to manage with current oligodendroglioma therapies, which typically involve radiotherapy and chemotherapy with temozolomide or the PCV regimen in conjunction with surgical resection.

Structure–activity relationship analysis revealed that the thiophen-2-yl group at the C-2 position produced the lowest IC50 values in both series, lower than those of their phenyl-substituted counterparts. Within compounds B, the activity order was B2 with the thienyl substituent, followed by B1 with pyridin-4-yl, B4 with 4-methylphenyl, and B3 with 4-fluorophenyl. Notably, pyridin-4-yl was the least active substituent among compounds A but the second-most active among compounds B, indicating that its contribution to activity depends on the electronic and steric character of the C-5 substituent. The thienyl compounds also possessed the highest selectivity indices in both series, suggesting that the thiophen-2-yl group was beneficial not only for cytotoxic potency but also for selectivity toward HS683 cells over normal astrocytes.

Molecular docking studies were performed against three kinase targets selected for their relevance to glioma pathogenesis: phosphatidylinositol 3-kinase alpha, cyclin-dependent kinase 2, and focal adhesion kinase. PI3Kα was included because of its role in the PI3K/AKT/mTOR pathway, CDK2 was included because of its overexpression in low-grade glioma subtypes, and FAK was selected based on its overexpression in glioma. The docking protocol was validated by re-docking the co-crystallized ligands, with root-mean-square deviation values all below 2.0 Å, confirming that the computational approach reliably reproduced experimental binding modes. Against PI3Kα, compounds B1 and B2 formed the strongest predicted interactions in the study, both forming hydrogen-acceptor contacts with LYS890 at distances of approximately 2.95 Å, with per-contact interaction energies of −9.0 and −8.8 kcal/mol respectively, involving the nitrile nitrogen of the 4-cyanophenyl group.

Against CDK2, compounds A produced scores of −6.654 to −7.087 kcal/mol, while compounds B ranged from −5.914 to −6.101 kcal/mol. B1 formed the richest interaction network among compounds B, with six contacts including two hydrogen-donor/acceptor interactions with LEU83 and PHE82, two hydrogen-acceptor contacts with LYS129 and ASN132, and a π–H contact with ILE10. B2 achieved a hydrogen-donor interaction between its sulfur atom and ASP145, suggesting that the sulfur atom of the thiophen-2-yl group is directly involved in the interaction. Against FAK, A2 achieved the strongest score among the synthesized compounds, and in both A2 and B2 the oxadiazole ring nitrogens served as the primary interaction atoms, forming two hydrogen-acceptor contacts with CYS502. This sulfur-specific contact with ASP145 was not observed for the phenyl- or heteroaryl-substituted analogs, providing a computational rationale for the superior activity of the thienyl compounds.

All seven compounds satisfied Lipinski’s rule of five, with molecular weights ranging from 248.24 to 319.68 g/mol and cLogP values ranging from 2.13 to 3.25, indicating moderate lipophilicity suitable for membrane permeation. The synthesized compounds had no hydrogen-bond donors and four to six hydrogen-bond acceptors, all below the maximum recommended limit. Topological polar surface area values ranged from 62.71 to 112.98 Ų, with compounds A showing higher values than compounds B. All final compounds were predicted to have high gastrointestinal absorption, and none were predicted to act as P-glycoprotein substrates, which may indicate a lower likelihood of efflux-mediated resistance. Notably, B1, B3, and B4 were predicted to permeate the blood–brain barrier, a relevant physicochemical feature for compounds intended to target glioma, although these predictions reflect theoretical permeability rather than confirmed central nervous system distribution and would require experimental validation.

The authors acknowledge that the proposed kinase targets are based on molecular docking and require experimental confirmation, and that further evaluation across additional glioma cell lines and in vivo models would help establish the broader therapeutic relevance of B2. Within the context of prior research, thioacetamide-based 1,3,4-oxadiazole derivatives have shown activity against C6 rat glioma cells, while ferulic acid- and caffeic acid-based oxadiazole hybrid derivatives have demonstrated activity against human glioblastoma cell lines U87, T98G, and LN229. Oxadiazole-based Akt/FAK inhibitors have also shown cytotoxic effects against C6 cells, supporting the relevance of FAK as a target within this chemical class. B2 extends this body of evidence to a previously unexamined glioma cell line and substituent pattern, reinforcing its potential as a lead candidate for future anti-glioma development.

Subject of Research: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article Title: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article References: Hashim, R. J., Alsaad, H. N., & Salman, H. H. (2026). 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking. Pharmacia, 73, Article e198079. https://doi.org/10.3897/pharmacia.73.e198079

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e198079

Keywords: 1,3,4-oxadiazole, anti-glioma agents, HS683, oligodendroglioma, molecular docking, MTT assay, selectivity index, drug-likeness, medicinal chemistry, kinase inhibitors, Oxadiazole, derivatives

The chemistry behind the excitement is elegantly simple. A Schiff base forms when the nitrogen lone pair of a primary amine attacks the electrophilic carbonyl carbon of an aldehyde or ketone, producing a fleeting carbinolamine intermediate that dehydrates to yield the characteristic azomethine group, R-CH=NR’. This imine nitrogen is the secret weapon: it donates electron density to almost any metal ion, anchoring the organic ligand to metals such as cobalt, nickel, copper, zinc, cadmium, vanadium, platinum and even rare earth elements. Depending on the ligand design, the resulting complexes can be mononuclear or polynuclear, homoleptic or heteroleptic, and can adopt geometries ranging from square planar and tetrahedral to octahedral and distorted pentagonal bipyramidal, as confirmed repeatedly by single-crystal X-ray diffraction.

Why does wrapping an organic molecule around a metal ion so often boost its biological punch? The review invokes two classical explanations. Overton’s concept suggests that chelation increases the lipophilicity of a compound, allowing it to slip more easily through the lipid membranes that guard bacterial and fungal cells. Tweedy’s chelation theory adds that coordination reduces the polarity of the metal ion by sharing its positive charge with the donor atoms, and may even delocalize electron density across the entire chelate ring. The result is a complex that penetrates cells more readily and then interferes with essential enzymatic processes. Electron-withdrawing and electron-donating substituents on the ligand fine-tune this electrophilicity and lipophilicity, which is why small structural changes can produce large swings in activity.

The antimicrobial evidence assembled in the review is extensive. In one representative study, cobalt, nickel, copper and zinc complexes of a Schiff base derived from 2-hydroxy-3-methoxy-5-nitrobenzaldehyde showed higher activity against Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa and Escherichia coli than the standard drugs ampicillin and chloramphenicol, and outperformed nystatin and griseofulvin against Candida albicans and other fungi. Elsewhere, a vanadium(IV) complex of a xipamide-salicylaldimine ligand beat both the free ligand and the parent drug griseofulvin against Aspergillus niger and Aspergillus flavus, while a copper complex built from a benzo[d][1,3]dioxole scaffold topped the screen against S. aureus and Klebsiella species.

Metal identity matters enormously, and the review documents clear activity trends across entire series. For complexes of a cuminaldehyde-L-histidine Schiff base, the antimicrobial ranking ran ligand < Zn(II) < Co(II) < Ni(II) < Cu(II), with the copper complex the strongest against E. coli, S. aureus and Aspergillus flavus. A similar hierarchy, Cu(II) > Co(II) > Ni(II) > Zn(II) > free ligand, appeared for tetradentate complexes derived from 2′,4′-dihydroxyacetophenone and ethylenediamine. Yet the pattern is not universal: cadmium and mercury complexes of furan-based Schiff bases showed remarkable activity, a zinc complex of a triazole-thiol ligand outshone its rivals against nine foodborne pathogens, and in one quinoline-derived series the free ligand actually beat most of its metal complexes. Geometry plays a role too, with a distorted tetrahedral Cu(II) sulfonamide complex outperforming its square planar Pd(II) analogue.

On the anticancer front, the review catalogues dozens of in vitro screens against cell lines spanning breast (MCF-7, MDA-MB-231), cervical (HeLa), colon (HT29, HCT116), liver (HepG2), lung (A549, H1299) and prostate (PC-3) cancers, most commonly using the MTT viability assay. Some results are eye-catching. A platinum(II) complex of naphthalene-derived hydrazinecarbothioamides exceeded the activity of cisplatin itself against MCF-7 breast cancer cells. A copper complex of a sulfamethoxazole Schiff base outperformed both cisplatin and carboplatin in the MDA-MB-231 breast cancer line. A cadmium complex achieved an IC50 of just 9 micrograms per millilitre against MCF-7 cells, and a zinc thiazole complex posted IC50 values between 5.3 and 6.2 micrograms per millilitre across four cell lines, though still short of doxorubicin.

Not every result is a triumph, and the review is candid about the failures. Copper complexes of dichloro-salicylidene sulfonamides fell short of cisplatin against MDA-MB-231 cells. Cobalt, nickel and copper chromone-thiadiazole complexes showed antitumor activity against HepG2 cells with IC50 values of roughly 18 to 20 micrograms per millilitre, well behind doxorubicin’s 4.73. In a series of dithiocarbazate zinc complexes, every ligand and complex was less active than the fluorouracil standard. These negative results matter: they map the boundaries of the field and underscore that metal choice, ligand substitution and cellular context jointly determine whether a chelate becomes a drug candidate or a dead end.

Beyond the petri dish, Schiff base metal complexes are proving useful across a surprising breadth of applications. Cobalt, iron and ruthenium complexes of hydroxybenzaldehyde-derived ligands catalyze the oxidation of cyclohexane to cyclohexanol; tridentate organocobalt complexes initiate emulsion polymerizations; and isothiosemicarbazone complexes exhibit nonlinear optical properties. Amino acid Schiff base complexes serve as radiotracers in nuclear medicine, macrocyclic dithiocarbazate complexes model oxygen transport in respiratory systems, and a benzofuran derivative related to these ligands acts as an antioxidant. The review also notes roles in sensors, pigments and dyes, polymer stabilization and analytical chemistry, reflecting the same coordination versatility that underpins the biological activity.

The authors conclude that the azomethine group is the common thread binding this vast literature together, and that metal complexation consistently enhances biological efficiency relative to the free ligands. For a field racing to find new antibiotics as resistance spreads and new cytotoxins as tumors evolve, Schiff base chelates offer a modular, synthetically accessible scaffold where chemists can dial in metal, geometry and substituents almost at will. The challenge now, the review implies, is translating these laboratory successes into compounds that survive the far harsher tests of pharmacokinetics, toxicity and clinical efficacy. But with copper complexes beating cisplatin in cell culture and simple chelates outperforming ampicillin, the 1864 discovery of Hugo Schiff may yet prove to be one of chemistry’s most enduring gifts to medicine.

Subject of Research: Antimicrobial and anticancer applications of Schiff base metal chelates

Article Title: A review on antimicrobial and anticancer applications of Schiff base chelates

Article References: Maruthavani, M., & Gomathi, V. (2026). A review on antimicrobial and anticancer applications of Schiff base chelates. Discover Chemistry, 3(1), Article 453. https://doi.org/10.1007/s44371-026-00845-9

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00845-9

Keywords: Schiff base, metal complexes, coordination chemistry, antimicrobial activity, anticancer activity, azomethine, chelation theory, IC50, medicinal inorganic chemistry, MTT assay, bioinorganic chemistry, drug resistance

Leishmaniasis remains one of the most burdensome parasitic diseases worldwide, presenting in cutaneous, mucocutaneous and visceral forms. The visceral form can be fatal if untreated, while the cutaneous form causes disfiguring skin lesions and lasting stigma. Existing therapies rely heavily on pentavalent antimonials such as Glucantim, the meglumine antimoniate formulation used as the comparator in this study, along with newer agents like miltefosine and amphotericin B. All of these carry significant drawbacks: antimonials require injections over weeks, cause cardiac and hepatic toxicity, and have lost effectiveness in some endemic regions where resistant parasite strains circulate. The limitations of the current pharmacopoeia are precisely why the Iranian team turned to natural toxins, a class of molecules evolution has refined to disrupt cells with remarkable efficiency.

The study compared two test compounds against the standard drug. The first was crude venom collected from the western honey bee, Apis mellifera, a complex cocktail of peptides and enzymes including melittin, apamin and phospholipase A2. The second was purified bee venom phospholipase A2, abbreviated bvPLA2, an enzyme that hydrolyzes phospholipids in cell membranes and is a major allergenic and pharmacologically active component of the venom. By testing both the whole venom and its isolated enzyme, the researchers could ask whether the anti-parasitic effect resides in the phospholipase itself or in the broader mixture, a question that matters greatly for any future effort to develop a tolerable medicine.

Methodologically, the team worked entirely in vitro, using the promastigote stage of L. major, the motile flagellated form that lives in the sand fly vector, and the amastigote stage, the round intracellular form that resides inside host macrophages and causes disease in humans. They also assessed toxicity toward RAW 264.7 macrophage cells, a standard murine macrophage line, using the MTT assay, a colorimetric test in which metabolically active cells convert a yellow tetrazolium salt into a purple formazan product, allowing viability to be quantified by absorbance. From these measurements the researchers calculated the CC50, the concentration killing half of the host cells, and the IC50, the concentration inhibiting half of the parasites, across 24, 48 and 72 hour exposure windows, with statistical analysis performed in GraphPad Prism.

The cytotoxicity results revealed a striking difference between the two compounds. Crude bee venom proved highly toxic to macrophages, with a CC50 of just 2.17 micrograms per milliliter and complete host-cell mortality at the later 48 and 72 hour time points. Purified bvPLA2, by contrast, was far gentler on the host cells, with CC50 values of 45.89, 36.22 and 86.01 micrograms per milliliter at 24, 48 and 72 hours respectively. This separation matters because a useful anti-parasitic drug must kill the parasite at concentrations that leave host cells largely unharmed, a balance expressed as the selectivity index. The enzyme’s much wider margin between parasite inhibition and host toxicity suggests that the crude venom’s other constituents, most likely membrane-lytic peptides such as melittin, drive the host-cell killing rather than the phospholipase itself.

Against the parasites, both compounds showed dose-dependent inhibition. On promastigotes, the inhibitory effect was evident from the lowest tested concentration at both time points examined. On the intracellular amastigotes, the clinically relevant stage, crude bee venom produced no significant inhibition at lower concentrations, whereas bvPLA2 significantly suppressed amastigote viability at both incubation times. At higher concentrations, however, viability fell more steeply in the crude venom treatments, indicating that the full venom mixture retains potent but indiscriminate lethal activity. Interestingly, when the researchers compared inhibition at constant concentrations between 24 and 48 hours, the effect either diminished or lost statistical significance at the longer exposure, an unexpected pattern that the authors note may reflect compensatory parasite responses or assay dynamics and that warrants further investigation.

The headline numbers came at the 48 hour mark. Crude venom achieved IC50 values of 4.89 micrograms per milliliter against promastigotes and 6.07 against amastigotes, while bvPLA2 recorded 5.76 and 9.03 micrograms per milliliter respectively. Both figures were significantly lower than the IC50 of Glucantim, the standard antimonial drug, with a probability value below 0.0001. In plain terms, on a pure potency basis, the bee-derived compounds outperformed the frontline therapy in this assay system. The researchers also observed an anomaly in the bvPLA2 data: MTT absorbance values rose above baseline at the first four enzyme concentrations after 48 hours, a pattern that could indicate a proliferative or metabolic stimulation of host cells at low enzyme doses and that the team flags as deserving of dedicated follow-up.

Mechanistically, the findings fit a broader literature on secretory phospholipase A2 enzymes as anti-parasitic agents. Leishmania parasites depend heavily on membrane phospholipid dynamics for host-cell invasion, intracellular survival and immune evasion, and their plasma membranes are rich in substrates that bvPLA2 can hydrolyze. Enzymatic disruption of these membranes could compromise the parasite’s integrity or its ability to remodel the parasitophorous vacuole it inhabits inside macrophages. Snake venom phospholipases have shown similar anti-leishmanial effects in earlier studies, and the present work extends that logic to the bee-derived enzyme. Because the purified enzyme is less cytotoxic than the whole venom, it offers a more plausible starting point for medicinal chemistry, where enzymatic activity could be tuned, or synthetic peptide analogues developed, to maximize parasite selectivity.

The authors are careful about scope. This is an in vitro study, and the leap from a culture dish to a patient involves pharmacokinetics, immunogenicity, delivery to infected macrophages and the formidable allergenic potential of bee venom components, since bvPLA2 is a principal trigger of bee-sting anaphylaxis. The anomalous MTT signals and the waning of inhibition at longer exposures also mean the dose-response picture is not yet fully resolved. Still, the study, which was extracted from the thesis of lead author Pouria Kavousi and funded by the School of Medicine at Shahid Beheshti University of Medical Sciences, establishes a concrete benchmark: the first documented anti-leishmanial activity of bvPLA2, with potency exceeding the standard drug in vitro and a cytotoxicity profile far more favorable than that of the crude venom. The researchers suggest this opens new avenues for exploring the pharmacological and biotechnological potential of the compound, and it adds honey bee venom to the growing list of venom sources, from snakes to scorpions to cone snails, being mined for next-generation anti-parasitic leads.

For the global health community, the significance lies in the direction of travel rather than any immediate therapy. Roughly a billion people live in areas endemic for leishmaniasis, and the World Health Organization counts hundreds of thousands of new cases annually, yet no vaccine exists for humans and the drug pipeline is thin. Natural product screening of this kind, pairing crude extracts with purified constituents and rigorous host-cell toxicity controls, is exactly the kind of low-cost, hypothesis-generating work that can seed future drug discovery programs. If subsequent studies can confirm the mechanism, improve the selectivity index further and demonstrate efficacy in animal models, the enzyme that honey bees use to defend their hive may one day contribute to treating a disease that has defied conventional chemotherapy for decades.

Subject of Research: Anti-leishmanial activity of honey bee venom and its phospholipase A2 enzyme against Leishmania major in vitro

Article Title: A step forward to exploring the inhibitory effects of crude honey bee venom (Apis mellifera) and its derived phospholipase A2 (bvPLA2) against Leishmania major in vitro

Article References: Kavousi, P., Lasjerdi, Z., Tabaei, S. J. S., Taghipour, N., Koosha, M., Koochaki, A., & Vaziri, V. M. (2026). A step forward to exploring the inhibitory effects of crude honey bee venom (Apis mellifera) and its derived phospholipase A2 (bvPLA2) against Leishmania major in vitro. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05572-3

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05572-3

Keywords: Leishmania major, bee venom, phospholipase A2, leishmaniasis, Apis mellifera, antiparasitic agents, promastigotes, amastigotes, MTT assay, cytotoxicity, natural toxins, drug discovery

The research team began with a straightforward question: if edible mushrooms are increasingly recognized as reservoirs of bioactive anticancer compounds, what might P. eous hold? The species is known to be rich in phenolic and terpenoid constituents, two broad chemical families with well-documented biological activity, yet its potential against cancer cells had never been systematically evaluated. To answer the question, the investigators prepared a methanolic extract of the mushroom fruiting bodies and subjected it to gas chromatography-mass spectrometry, or GC-MS, a technique that vaporizes chemical compounds and separates them by mass, allowing researchers to identify individual molecules within a complex mixture. The spectral data, matched against reference libraries maintained by the National Institute of Standards and Technology, revealed a phytochemical profile that immediately caught the authors’ attention.

Among the compounds identified were carvacrol, quinic acid, and a derivative of cinnamic acid. Each of these molecules carries an established scientific pedigree. Carvacrol, the monoterpene phenol that gives oregano and thyme their characteristic aroma, has been repeatedly studied for antimicrobial, antioxidant, and pro-apoptotic effects in cancer models. Quinic acid, a cyclitol found in coffee and many plants, is a building block of chlorogenic acid and has been linked to anti-inflammatory and chemopreventive activity. Cinnamic acid derivatives, meanwhile, appear throughout the plant and fungal kingdoms and have been investigated for their ability to interfere with tumor cell proliferation. The presence of all three in a single mushroom extract suggested that P. eous might be more than an ordinary culinary fungus, prompting the team to move from chemical identification to biological testing.

The first biological assay targeted oxidative chemistry. The researchers used the DPPH assay, a widely employed colorimetric test in which the purple-colored free radical 2,2-diphenyl-1-picrylhydrazyl loses its absorbance when neutralized by antioxidants. The results were dramatic: at a concentration of 700 micrograms per milliliter, the P. eous extract scavenged 97.39 percent of the DPPH radicals, an efficiency approaching that of synthetic reference antioxidants. Complementing this, the team measured total phenolic content using the Folin-Ciocalteu assay, which quantifies phenolic compounds by their ability to reduce a phosphotungstic-phosphomolybdic acid reagent, expressed here in gallic acid equivalents. The extract yielded a total phenolic content of 2.80 plus or minus 0.04 milligrams of gallic acid equivalent per gram of dry weight. The strong radical-scavenging performance is consistent with the idea that phenolic compounds donate hydrogen atoms or electrons to stabilize reactive radicals, a mechanism thought to contribute to chemoprevention by protecting cellular DNA from oxidative damage.

The centerpiece of the study, however, was the cytotoxicity testing against MCF-7 cells, one of the most extensively characterized human breast cancer cell lines in existence. Originally isolated in 1970 from a patient with invasive breast carcinoma, MCF-7 cells are estrogen-receptor positive and serve as a standard in vitro model for hormone-responsive breast cancer, the most common malignancy in women worldwide. The researchers cultured the cells in Dulbecco’s Modified Eagle Medium supplemented with fetal bovine serum and exposed them to escalating concentrations of the mushroom extract. Cell viability was quantified with the MTT assay, a metabolic test in which living cells reduce a yellow tetrazolium salt into purple formazan crystals; the amount of formazan produced serves as a proxy for the number of metabolically active, surviving cells. Doxorubicin, a mainstay anthracycline chemotherapy drug, served as the positive control against which the extract’s performance could be benchmarked.

The outcome was unambiguous. The extract killed MCF-7 cells in a dose-dependent fashion, achieving a half-maximal inhibitory concentration, or IC50, of 82.69 micrograms per milliliter at the 24-hour time point. In pharmacological terms, the IC50 represents the concentration of a compound required to reduce cell viability by half, and values in the low tens to hundreds of micrograms per milliliter are considered meaningful starting points for natural product screening. Microscopic examination of the treated cultures revealed morphological changes characteristic of apoptosis, the programmed cell death pathway that cancer cells often evade. Cells exposed to higher concentrations of the extract displayed the shrinkage, rounding, and detachment that pathologists associate with cells undergoing self-destruction rather than simple toxic necrosis. Statistical analysis by analysis of variance followed by Tukey’s post-hoc test confirmed that the differences between treated and untreated groups were highly significant, with a p-value below 0.0001, meaning the probability that the observed effect arose by chance is vanishingly small.

The authors attribute the extract’s dual antioxidant and cytotoxic activity to its phenolic and terpenoid content, and the mechanistic logic is plausible. Phenolic compounds can act as pro-oxidants at high intracellular concentrations, tipping the redox balance of cancer cells, which already live under elevated oxidative stress, past the point of no return and triggering apoptotic signaling. Terpenoids such as carvacrol have been shown in other systems to disrupt mitochondrial membrane potential, activate caspase enzymes, and interfere with cell cycle progression. Quinic acid derivatives may contribute through modulation of inflammatory pathways that sustain tumor growth. It is important to stress, however, that the present study identifies associations rather than definitive mechanisms. The extract is a mixture of many compounds, and the specific molecule or combination of molecules responsible for killing MCF-7 cells has not yet been isolated or proven.

That caveat leads directly to the study’s stated limitations and next steps. The authors are explicit that further in vivo studies and compound purification are needed to confirm the observed effects and to clarify the underlying mechanisms. In vitro cell culture, while indispensable for screening, cannot capture the pharmacokinetics of a real organism: how a compound is absorbed, distributed, metabolized, and excreted, whether it reaches tumor tissue at active concentrations, and whether it harms healthy cells along the way. A crude methanolic extract that kills cancer cells in a dish may contain molecules that are too toxic, too unstable, or too poorly absorbed to ever become medicine. The purification pipeline, typically involving high-performance liquid chromatography fractionation followed by bioassay-guided testing, will be essential to isolate the active principles and determine whether a single compound or a synergistic ensemble is responsible.

Nevertheless, the study lands at a moment of surging interest in fungi as pharmaceutical factories. Mushrooms occupy a unique ecological niche as decomposers, and their evolutionary pressure to produce defensive secondary metabolites has equipped them with an extraordinary chemical arsenal. Established drugs derived from fungi include the statins, the immunosuppressant cyclosporine, and antibiotics such as penicillin, while mushroom-derived polysaccharides like lentinan from shiitake have been approved as adjuvant cancer therapies in some countries. Edible oyster mushrooms of the Pleurotus genus are particularly attractive candidates because they are cheap to cultivate on agricultural waste, fast-growing, and already consumed safely by millions of people, which simplifies the safety profile questions that plague many natural product candidates.

For now, the message for the public is one of measured enthusiasm rather than self-medication. Eating oyster mushrooms will not deliver the concentrated, chemically characterized extract tested in this study, and no clinical evidence yet supports any therapeutic use of P. eous in cancer patients. What the research does provide is a rigorous, statistically robust foundation for the next phase of investigation: isolating the active molecules, testing them against normal cells to establish selectivity, validating the findings in animal models, and ultimately, if the results hold, advancing toward clinical evaluation. Breast cancer remains one of the most prevalent malignancies worldwide, and the search for new agents, particularly those derived from accessible natural sources, remains urgent. A mushroom that most people walk past in the grocery aisle may, with enough scientific scrutiny, turn out to harbor chemistry worth far more than its weight in the produce bin. The journey from laboratory dish to pharmacy shelf is long and uncertain, but every credible candidate discovered along the way improves the odds.

Subject of Research: Anticancer and antioxidant potential of Pleurotus eous mushroom extract against human breast cancer MCF-7 cells in vitro

Article Title: Evaluation of the anticancer potential of Pleurotus eous against human breast cancer MCF-7 cell line

Article References: Al Qutaibi, M., & Kagne, S. R. (2026). Evaluation of the anticancer potential of Pleurotus eous against human breast cancer MCF-7 cell line. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05582-1

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05582-1

Keywords: Pleurotus eous, oyster mushroom, breast cancer, MCF-7, anticancer, antioxidant, GC-MS, MTT assay, carvacrol, phenolic compounds, apoptosis, natural products

The clinical problem the team set out to address is a familiar one. Ulcers and other lesions on the oral mucosa interfere with chewing and speech and can cause considerable pain, and their repair depends heavily on the behavior of human gingival fibroblasts. These cells migrate into the wound bed, proliferate, and lay down new extracellular matrix, including collagen, that closes the defect. Oxidative stress, driven by reactive oxygen species, damages fibroblasts and slows this sequence of events, delaying recovery. Because lychee seeds are rich in antioxidant phenolic and flavonoid compounds, and because previous work had suggested benefits for dermal wound healing, the researchers hypothesized that a crude lychee seed extract might protect or even stimulate gingival fibroblasts in ways that could accelerate oral tissue repair.

To prepare the test material, the team produced a crude extract by soaking lychee seed material in 95 percent ethanol, a standard approach for pulling out a broad spectrum of plant secondary metabolites. They then characterized the chemical composition of the extract using ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight tandem mass spectrometry, a sensitive analytical technique that separates compounds and identifies them by their mass fragmentation patterns. The analysis revealed 45 compounds spanning six chemical classes, among them 15 phenolic and flavonoid species. This chemical inventory matters because phenolics and flavonoids are the compounds most often associated with antioxidant and wound-healing activity in plant extracts, and knowing what is present provides a starting point for later work with purified constituents.

The biological experiments used the HGF-1 human gingival fibroblast cell line, a commercially available established line, treated with crude lychee seed extract across a wide concentration range from 0.1 to 100 micrograms per milliliter. Cytotoxicity was assessed with the MTT assay, a colorimetric test in which metabolically active cells convert a tetrazolium compound into a colored product whose absorbance can be measured, following the ISO 10993-5 standard for evaluating the biological safety of medical devices. Cell morphology was examined by phase-contrast microscopy to check for visible signs of damage or distress. According to the ISO threshold, cell viability above 70 percent indicates a non-cytotoxic material, and the extract met that criterion at concentrations from 0.1 up to 50 micrograms per milliliter.

At the highest concentration tested, 100 micrograms per milliliter, viability fell marginally below the 70 percent threshold, although the reduction did not reach statistical significance compared with untreated controls. The 50 and 100 microgram per milliliter doses also behaved differently in the functional assays, suppressing fibroblast growth rather than supporting it. This concentration-dependent pattern, in which low doses help and high doses hinder, is common in studies of plant extracts and reflects the dual nature of many plant polyphenols, which can act as protective antioxidants at low exposure but become pro-oxidant or otherwise disruptive at higher levels. For any future therapeutic application, the study suggests the useful window sits well below the cytotoxic boundary.

Proliferation was tracked with the MTT assay over seven days of continuous exposure. At low concentrations between 1 and 20 micrograms per milliliter, the extract significantly enhanced HGF-1 proliferation on day five. By day seven, the lowest dose tested, 0.1 micrograms per milliliter, produced the highest proliferation of all, reaching statistical significance at p less than 0.001 compared with the control. The authors analyzed the data with one-way analysis of variance followed by Tukey’s honestly significant difference post-hoc test, with significance set at p less than 0.05. The result that the most dilute dose ultimately drove the strongest growth response hints that the active compounds are potent and that more is not necessarily better, a theme that recurred in the migration experiments.

Migration, the other half of the wound-repair equation, was evaluated with an in vitro scratch assay, a widely used technique in which a sterile pipette tip drags a straight gap through a confluent cell monolayer, mimicking a wound, and researchers then photograph the gap at intervals to measure how quickly cells close it. The team measured gap closure at 8, 16 and 24 hours after treatment. Concentrations from 0.1 to 20 micrograms per milliliter accelerated closure of the scratch at the eight-hour mark, and the middle-range doses of 5 and 10 micrograms per milliliter produced the greatest closure by 24 hours. In contrast, the 50 and 100 microgram per milliliter doses delayed gap closure, reinforcing the picture that moderate doses support the migratory behavior fibroblasts need to invade a wound while high doses impair it.

Putting the numbers together, the authors identify 0.1 to 10 micrograms per milliliter as the most promising concentration range, one in which the crude extract is clearly non-cytotoxic, stimulates fibroblast proliferation, and speeds wound closure in the scratch model. They are careful about the limits of interpretation. The study demonstrated an association between extract exposure and improved cellular outcomes but did not determine the underlying molecular mechanisms. The extract contains a complex mixture, and any of its 45 identified compounds, alone or in combination, could be responsible for the effects. Possible pathways that the authors discuss in the broader context include antioxidant defense signaling through the Nrf2 pathway and growth factor signaling, but these remain hypotheses for future experiments rather than demonstrated findings of this study.

The researchers also frame the work within the biology of oral wound healing. Fibroblast proliferation and migration are early and essential steps in granulation tissue formation, and fibroblasts respond to signals such as transforming growth factor beta 1 and fibroblast growth factor 2 while producing collagen and remodeling the matrix with matrix metalloproteinases. Oxidative stress in the wound environment, elevated reactive oxygen species and inflammatory cytokines such as interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha can all impair these processes. An extract rich in antioxidant phenolics could, in principle, shift that balance, which is why the authors suggest that crude lychee seed extract and its purified constituents merit further investigation as agents for promoting oral soft tissue healing.

For now, the caveats are substantial. Everything reported here happened in a dish, using a single established cell line and a crude, chemically unstandardized extract, and the authors note that no specific funding body supported the research and that they declare no competing interests. The jump from a scratch assay to a mouthwash, gel or dressing that safely accelerates ulcer healing in patients requires animal studies, mechanism work, extract standardization and eventually clinical trials. Still, the study opens an unexpected door. Lychee seeds are an abundant agricultural byproduct, largely thrown away after the fruit is eaten, and if their phenolic cargo can be harnessed for oral tissue repair, a tropical fruit pit could someday find an unlikely second life in dental medicine. The next step, the authors suggest, is to isolate and test the individual purified compounds responsible for the proliferative and migratory effects they observed.

Subject of Research: Effects of crude lychee seed extract on proliferation and migration of human gingival fibroblasts in vitro

Article Title: In vitro assessment of cell proliferation and migration induced by crude lychee seed extract in human gingival fibroblast cells (HGF-1)

Article References: Ruensukon, T., Chuenjitkuntaworn, B., Tengrungsun, T., Pachimsawat, P., Tamura, Y., & Fuangtharnthip, P. (2026). In vitro assessment of cell proliferation and migration induced by crude lychee seed extract in human gingival fibroblast cells (HGF-1). BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05579-w

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05579-w

Keywords: lychee seed extract, human gingival fibroblasts, wound healing, cell proliferation, cell migration, oral ulcers, natural products, phenolic compounds, flavonoids, MTT assay, scratch assay, cytotoxicity

The 1,3,4-oxadiazole is a compact five-membered ring containing two nitrogen atoms and one oxygen atom, and it has long been a favourite building block in medicinal chemistry because it appears in compounds with antibacterial, antifungal, anti-inflammatory and anticancer activity. The researchers, led by Rekha Singh and Jagadish Singh of Guru Ghasidas Vishwavidyalaya in Bilaspur, together with Balaji Wamanrao Matore and colleagues, drew on two decades of their own prior work with this scaffold. Their design strategy placed a phenyl ring directly on the oxadiazole core, a motif also found in the approved drug zibotentan, and attached a second chlorinated phenyl ring through an imine, or CH=N, linker at the five-position of the ring.

Synthesis proceeded in three straightforward steps. Substituted aldehydes were first condensed with semicarbazide hydrochloride in ethanol to form Schiff base intermediates, which were then cyclised with iodine and potassium carbonate in 1,4-dioxane at 80 degrees Celsius to build the oxadiazole ring. A final condensation with different chloro-substituted aldehydes delivered the nine target compounds, R1 through R9, in yields above 90 percent. Every product was confirmed by FT-IR, proton NMR and mass spectrometry, with the diagnostic imine proton appearing between 8.73 and 8.99 parts per million in the NMR spectra, and melting points recorded for each purified solid.

Before any wet-lab testing, the team ran a battery of computational experiments. Density functional theory calculations using the DMol3 code suggested that all nine compounds are more chemically reactive than the kinase inhibitor sorafenib, with R3, R4 and R6 showing the smallest HOMO-LUMO gaps at 0.086 Hartree, a measure that correlates with a molecule’s willingness to engage in electronic interactions. Target prediction servers, including PASS and SwissTargetPrediction, then pointed the researchers toward kinase receptors, a family of enzymes heavily implicated in breast cancer biology through receptors such as VEGFR2, EGFR, PDGFR and HER2.

VEGFR2, the vascular endothelial growth factor receptor 2, emerged as the priority target because of its central role in angiogenesis, the process by which tumours recruit new blood vessels to fuel their growth and spread. Blocking VEGFR2 is a clinically validated strategy in breast cancer management, and the researchers selected the crystal structure 4ASD from the Protein Data Bank for docking studies. After validating their protocol by re-docking the co-crystallised ligand and achieving root-mean-square deviations well below the accepted two angstrom threshold, they docked all nine compounds into the ATP binding pocket using three independent algorithms: CDOCKER, LibDock and AutoDock Vina.

The docking results told a remarkably consistent story. Compound R3 achieved the highest CDOCKER interaction energy at 41.54 and the best LibDock score at 130.38, and it formed fifteen separate contacts with the protein, including hydrogen bonds to GLU885, ASP1046 and LYS868, three residues known to stabilise ATP-competitive inhibitors at the hinge region of the kinase. Twelve additional hydrophobic contacts with residues such as LEU840, VAL848, PHE918 and CYS1045 locked the molecule deep in the pocket. Fourteen of these interactions were shared with the co-crystallised reference ligand, meaning R3 essentially mimics the binding mode of a proven VEGFR2 inhibitor. Binding free energy calculations confirmed the picture, with R3 showing the most favourable stability of the series at minus 84.42 kilocalories per mole, compared with minus 142.01 for sorafenib.

Structure-activity relationship analysis revealed the decisive role of chlorine positioning. Derivatives bearing meta and para chloro substituents on their phenyl rings, compounds R1 through R4, consistently outperformed those with ortho substitution, compounds R5 through R9. The explanation is steric: an ortho chlorine crowds the space near the imine linker and prevents the molecule from adopting the flat, extended conformation needed to slot into the VEGFR2 pocket. The ortho-substituted compounds formed almost no favourable interactions in docking, showed weaker binding free energies, and translated this deficit directly into higher IC50 values in the cell assays. It is a textbook example of how a single atom, moved a few angstroms, can flip a molecule from active to inert.

The computational predictions were then put to the test in the laboratory. Using the MTT assay against MCF-7 breast cancer cells at concentrations ranging from 5 to 80 micromolar, all nine compounds showed moderate to potent, concentration-dependent cytotoxicity, with IC50 values spanning 8.068 to 17.343 micromolar. Three compounds, R1, R3 and R4, fell below the 10 micromolar threshold, and R3 led the series at 8.068 micromolar, close to the 4.051 micromolar recorded for doxorubicin under the same conditions. Microscopy of treated cultures showed reduced cell density and altered morphology relative to untreated controls, consistent with the viability data.

Pharmacokinetic modelling added a further layer of optimism. SwissADME predictions indicated high gastrointestinal absorption and good oral bioavailability for the whole series, with moderate lipophilicity, LogP values of 3.3 to 3.5, and a low topological polar surface area of 51.28 square angstroms, a balance well suited to membrane permeability. The ProTox-II server classified all compounds in toxicity class 4 with an LD50 of 375 milligrams per kilogram and predicted them to be non-carcinogenic, non-mutagenic and non-immunotoxic, although moderate hepatotoxicity was flagged for the series, mirroring the profile of sorafenib itself. The authors note two caveats for future optimisation: moderate aqueous solubility may complicate formulation, and the predicted ability to cross the blood-brain barrier raises the possibility of off-target central nervous system exposure that must be managed in an anticancer context.

The study’s authors are careful to frame the work as an early-stage screening effort. MCF-7 served as the initial model, and broader evaluation across additional cancer cell lines and normal cell models will be needed to establish selectivity and safety, particularly for R3, which the team identifies as the lead candidate for further development. Even so, the internal consistency of the data is compelling: the same substitution pattern that produced the best docking scores also produced the strongest binding free energies and the lowest IC50 values, and the key residues engaged by R3 match those exploited by clinically approved VEGFR2 inhibitors such as sorafenib. For a scaffold as chemically accessible as the 1,3,4-oxadiazole, synthesised in three steps from cheap starting materials with yields above 90 percent, that combination of potency, predictability and synthetic simplicity makes R3 a lead worth watching as VEGFR2-targeted breast cancer drug discovery moves forward.

Subject of Research: Design and evaluation of 1,3,4-oxadiazole derivatives as VEGFR2-targeted anticancer agents against breast cancer

Article Title: Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer

Article References: Singh, R., Matore, B. W., Murmu, A., Lakra, N., Banjare, P., Namdeo, K. P., Roy, P. P., & Singh, J. (2026). Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer. Discover Chemistry, 3(1), Article 539. https://doi.org/10.1007/s44371-026-00898-w

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00898-w

Keywords: breast cancer, 1,3,4-oxadiazole, VEGFR2, MCF-7, molecular docking, structure-activity relationship, ADMET, drug discovery, angiogenesis, kinase inhibitors, MTT assay, medicinal chemistry

The rationale behind the work rests on a strategy that chemists call molecular hybridization. Rather than screening random libraries or chasing a single protein target, the researchers deliberately stitched together two pharmacologically privileged fragments, each with an impressive track record of its own. The pyrimidine ring, a six-membered aromatic system containing two nitrogen atoms, is a core component of the nucleobases that make up DNA and RNA, and it appears in numerous FDA-approved medicines. Perhaps the most famous modern example is osimertinib, a tyrosine kinase inhibitor used to treat lung cancer, in which the pyrimidine moiety is an essential part of the molecular framework that engages its biological target.

The second fragment, the 1,3,4-oxadiazole, is a five-membered ring containing two nitrogen atoms and one oxygen atom. Its azole functional group, characterized by alternating carbon-nitrogen double bonds, acts as a hydrogen-bond acceptor and can form strong interactions with the binding pockets of proteins. This ring has been incorporated into agents with antidepressant, antiviral, anti-inflammatory, antitubercular, antimitotic, and anticancer activities. AstraZeneca researchers developed zibotentan, a molecule containing the 1,3,4-oxadiazole unit, as an anticancer drug candidate for prostate cancer, illustrating the ring’s clinical relevance. By combining these two motifs through a flexible phenoxy linker, the team hoped to create a structurally complementary scaffold whose biological activity would exceed the sum of its parts.

The synthetic route begins with an inexpensive and familiar starting material: 2-hydroxybenzoic acid, better known as salicylic acid. The researchers first esterified the acid with methanol under sulfuric acid catalysis, a twelve-hour reflux that delivered methyl 2-hydroxybenzoate in 92 percent yield. Treatment of this ester with hydrazine hydrate converted it into 2-hydroxybenzohydrazide, a hydrazide bearing a free phenolic hydroxyl group that would prove crucial in later steps. Each intermediate was rigorously characterized using proton and carbon-13 nuclear magnetic resonance spectroscopy, mass spectrometry, and melting point analysis, with high-resolution mass measurements matching calculated values to within a few thousandths of a mass unit.

The pivotal ring-forming step came next. The hydrazide was coupled with pyrimidine-5-carboxylic acid using HATU, a powerful peptide-coupling reagent, together with triethylamine in dry tetrahydrofuran. Adding Burgess reagent, a mild dehydrating agent, then cyclodehydrated the resulting diacylhydrazide intermediate to close the 1,3,4-oxadiazole ring, furnishing the key phenolic oxadiazole building block in 60 percent yield. This intermediate was subsequently reacted with 2,4-dichloropyrimidine in the presence of the base DIPEA, which selectively displaced one of the two chlorine atoms through the phenolic oxygen, producing a chloropyrimidine ether in 79 percent yield. The remaining chlorine atom served as a chemical handle for the final diversification step.

That final step is where the library took shape. The chloropyrimidine intermediate was heated under reflux with ten different aryl amines, each catalyzed by a small amount of p-toluenesulfonic acid, generating ten target compounds designated 11a through 11j. The aryl amines spanned a deliberate range of electronic characters: electron-donating methoxy groups in single, double, and triple arrangements; simple methyl substituents; a dimethylamino group; and electron-withdrawing chloro, bromo, nitro, and dinitro groups. Yields for the final coupling ranged from 68 to 83 percent, and the products, mostly crystalline white solids with melting points approaching or exceeding 280 degrees Celsius, were purified by column chromatography and confirmed by the full battery of analytical techniques.

With the library in hand, the team turned to biological testing using the MTT assay, a colorimetric method in which living cells convert a yellow tetrazolium dye into purple formazan crystals, allowing cell viability to be quantified by light absorption at 570 nanometers. Four human cancer cell lines were challenged with the compounds: MCF-7 breast cancer cells, A549 lung cancer cells, Colo-205 colon cancer cells, and A2780 ovarian cancer cells. Etoposide, a topoisomerase inhibitor widely used in chemotherapy, served as the positive control, and a range of concentrations from 0.5 to 2 micromolar was tested over 24-hour incubations. Critically, the compounds were also tested against Vero cells, a normal kidney epithelial cell line from the African green monkey, to gauge whether the cytotoxicity was selective for cancer cells.

The results were striking. Compound 11a, bearing a 3,4,5-trimethoxyphenyl group, emerged as the star of the series, with half-maximal inhibitory concentrations of 0.13 micromolar against MCF-7 breast cancer cells, 0.27 micromolar against A549 lung cancer cells, 0.32 micromolar against Colo-205 colon cancer cells, and 0.17 micromolar against A2780 ovarian cancer cells. Against breast and ovarian cancer cells, this single compound was roughly an order of magnitude more potent than etoposide, which registered 2.19 and 1.38 micromolar respectively in those lines. Compounds 11b through 11f, spanning the dimethoxy, monomethoxy, methyl, and dimethylamino variants, also beat the positive control in most cell lines, with IC50 values ranging from roughly 0.4 to 3.3 micromolar. The electron-poor compounds 11g through 11j, carrying halogen and nitro substituents, were consistently the weakest performers, with activities in the 3.7 to 4.6 micromolar range and, in some cases, no detectable activity against particular cell lines.

Just as important as the potency was the selectivity. Every one of the ten compounds showed markedly weaker toxicity toward normal Vero cells, with IC50 values all exceeding 28 micromolar, and some exceeding 38 micromolar. That means the best compound was more than two hundred times more toxic to breast cancer cells than to normal kidney cells, a therapeutic window that, if it holds up in more advanced models, would be highly desirable for an anticancer agent. The structure-activity relationship that emerged from the data is clear and chemically intuitive: electron-donating methoxy groups favor activity, and the more methoxy groups, the better, with the 3,4,5-trimethoxy pattern of 11a standing at the top of the hierarchy. Swapping methoxy for methyl groups diminished potency, and electron-withdrawing substituents eroded it further, suggesting that the electronic richness of the aryl amine fragment plays a decisive role in whatever interaction these molecules make inside cancer cells.

The trimethoxyphenyl motif itself carries an intriguing pedigree, appearing in other biologically active natural products and synthetic agents, and its prominence here hints at a possible binding interaction worth pursuing. The authors are careful to frame this as preliminary work: the compounds were tested in vitro, no molecular target has yet been identified, and the mechanism by which these hybrids kill cancer cells remains to be established. The next steps for such a program typically involve expanding the cell panel, probing the compounds’ effects on cell cycle and apoptosis, identifying the protein targets through affinity-based methods, and evaluating pharmacokinetic properties. Still, the study demonstrates the power of rational fragment fusion in medicinal chemistry. By welding a pyrimidine ring, the scaffold of a blockbuster lung cancer drug, to a 1,3,4-oxadiazole, the ring at the heart of a prostate cancer candidate, and tuning the aryl amine cap with methoxy groups, the researchers have produced a lead compound whose nanomolar potency and favorable selectivity profile make it a genuinely promising starting point for further anticancer drug development.

Subject of Research: Synthesis and anticancer evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole hybrid compounds

Article Title: Synthesis and biological evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole derivatives as potential anticancer agents

Article References: Mukkavilli, P., Konidena, L. N. S., Valluru, K. R., Somaiah, N., & Subbarao, M. (2026). Synthesis and biological evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole derivatives as potential anticancer agents. Results in Chemistry, 31, Article 103865. https://doi.org/10.1016/j.rechem.2026.103865

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103865

Keywords: pyrimidine, 1,3,4-oxadiazole, anticancer agents, molecular hybridization, MTT assay, MCF-7, A549, structure-activity relationship, medicinal chemistry, heterocyclic compounds, etoposide, drug discovery

The stakes could hardly be higher. Brain tumors remain among the most lethal malignancies in medicine, characterized by dismal prognoses and stubborn resistance to conventional therapies, while neuroblastoma—a cancer of the sympathetic nervous system that strikes mainly in early childhood—poses its own formidable treatment challenges. Patients undergoing intensive chemotherapy for these diseases are profoundly immunosuppressed, and bacterial infections during treatment are common, feared, and frequently fatal. Antibiotic prophylaxis and empiric treatment are therefore standard practice, not optional extras. Clinical studies have documented significant rates of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma, and febrile neutropenia in solid tumor patients is routinely managed with broad-spectrum cephalosporins like cefazolin’s relatives. If those protective drugs simultaneously erode the efficacy of the anticancer regimen, the trade-off at the bedside becomes far more complicated than anyone assumed.

The Turkish team, led by İlayda Şişli together with Melek Yüce and Esra Albayrak, set out to probe precisely this dual role. Their question was deceptively simple: what happens to cancer cells when a widely used antibiotic and a chemotherapy drug share the same culture medium? Cefazolin, marketed in some countries as Cefamezin, is a beta-lactam antibiotic that works by disrupting bacterial cell wall synthesis—utterly irrelevant machinery for human cells, which have no cell walls. Yet a accumulating literature suggests cephalosporins are not pharmacologically inert toward tumor cells. Some studies have reported that certain cephalosporins can suppress cancer growth, for example by triggering ferroptosis, an iron-dependent form of cell death, in nasopharyngeal carcinoma cells, or by targeting Aurora B kinase in lung cancer models. Others have found the opposite: ceftazidime and cefepime were shown to antagonize the effect of 5-fluorouracil in colon cancer cells. The picture is inconsistent, drug-specific, and cell-type-specific—which is exactly why direct experimental testing matters.

To interrogate the interaction, the researchers used two complementary experimental readouts. The first was the MTT assay, a colorimetric test in which metabolically active cells convert a yellow tetrazolium compound into a purple formazan product; the amount of purple dye serves as a proxy for the number of viable, metabolically competent cells. The second was flow cytometry, a technique that fires cells one by one through a laser and quantifies their DNA content and fluorescent markers, allowing researchers to determine what fraction of the cell population sits in each phase of the cell cycle—G0/G1, S, G2/M—and what fraction has fallen into the sub-G0/G1 debris characteristic of dying cells. Together, these methods capture both the net effect on cell survival and the mechanistic fingerprint of how the drugs act on the cell division machinery.

The results were clear on both fronts. Irinotecan, a topoisomerase I inhibitor that works by trapping the enzyme responsible for relieving torsional stress in DNA during replication, thereby converting an essential enzyme into a DNA-damaging poison, induced significant cytotoxicity in both LN-18 glioblastoma and SH-SY5Y neuroblastoma cells. Flow cytometry showed the expected signature: an increase in the sub-G0/G1 fraction, indicating cells with fragmented DNA heading toward death, alongside arrest in the S phase, where DNA replication stalls, and the G2/M phase, where cells with damaged DNA halt before mitosis. This is textbook topoisomerase poison behavior—the drug prevents cells from copying and dividing their genome cleanly, and the damaged cells accumulate and die.

Then came the twist. When cefazolin was added alongside irinotecan, the chemotherapy’s grip on the cells loosened. In the SH-SY5Y neuroblastoma cells, co-treatment with the antibiotic attenuated both the cytotoxicity and the cell cycle disruption that irinotecan alone had produced; the drug’s ability to push cells into the lethal sub-G0/G1 compartment and to arrest them in S and G2/M was measurably blunted. In the LN-18 glioblastoma cells, the pattern was similar but not identical: cefazolin partially weakened irinotecan’s inhibition of cell viability, while necrosis rates—death by a messier, non-programmed route—were not significantly altered. In both cell lines, the direction of the interaction was the same, and it was the wrong direction for a cancer patient: the antibiotic softened the chemotherapy’s blow.

What might explain this antagonism at the molecular level? The study does not pin down a mechanism, but the authors and the surrounding literature point to several plausible candidates. Antibiotics and chemotherapeutics can compete for cellular transport systems, altering how much drug actually reaches its intracellular target—a phenomenon first documented more than fifty years ago, when researchers showed that certain antibiotics interfered with the cellular transport and antitumor activity of methotrexate in leukemia cells. Antibiotics can also modulate drug efflux pumps such as BCRP/ABCG2, the molecular bouncers that expel chemotherapy agents from cells; indeed, one antibiotic, novobiocin, is famous precisely because it reverses such resistance. More speculatively, cefazolin could be altering mitochondrial function, reactive oxygen species generation, or the metabolic state of the tumor cells in ways that buffer them against topoisomerase-induced stress. Disentangling these possibilities will require the kind of mechanistic follow-up this in vitro study deliberately leaves open.

The broader context makes the finding more than a laboratory curiosity. A substantial clinical literature has already linked antibiotic exposure to worse cancer outcomes, most prominently with immune checkpoint inhibitors, where antibiotic use around the time of treatment has been associated with reduced clinical activity in advanced renal cell and non-small-cell lung cancer—largely attributed to disruption of the gut microbiome. A retrospective cohort study in glioblastoma patients has examined whether antibiotic drug use affects outcome and therapy-related toxicity, and reviews have framed antibiotics as a double-edged sword in oncology: indispensable against infection, potentially harmful against the tumor. Drug–drug interactions in cancer patients treated with oral anticancer agents are common and often overlooked, and fatal adverse drug events remain a sobering reminder that polypharmacy in oncology is a minefield. The new study extends this concern from the microbiome and the immune system down to the level of direct pharmacological interference between a cephalosporin and a topoisomerase inhibitor inside the tumor cell itself.

The researchers are careful about what their data can and cannot say. This was an in vitro study: two immortalized cell lines, culture dishes, and defined drug concentrations. Real glioblastomas and neuroblastomas live behind the blood–brain barrier, embedded in a microenvironment that no monolayer culture reproduces, and the concentrations and timing of cefazolin exposure in a treated patient differ from those in a flask. The authors explicitly note that their findings suggest cefazolin may antagonize the cytotoxic effects of irinotecan in vitro and underscore the need for further validation in in vivo and clinically relevant models. Animal studies and, ultimately, carefully designed clinical pharmacology studies would be needed before anyone could say whether a patient receiving cefazolin during irinotecan-based therapy actually experiences a meaningful reduction in tumor control. It is also worth remembering that irinotecan is not a mainstay of standard glioblastoma care, so the immediate clinical implications for current treatment protocols are limited; the finding speaks more to the principle than to a specific prescription today.

Even so, the message lands with force. Antibiotics are among the most frequently co-administered drugs in oncology, handed out for prophylaxis, for fever during neutropenia, and for intercurrent infections across every tumor type and every age group, from children with neuroblastoma to adults with glioblastoma. If a drug as ordinary as cefazolin can measurably weaken a chemotherapy agent in the dish, then the possibility deserves systematic scrutiny rather than assumption of safety. The study, funded by the Ondokuz Mayıs University Scientific Research Project Office and conducted with cell lines provided by Yeditepe University in Istanbul, is a small piece of evidence—but it points at a large blind spot. As cancer therapy grows ever more complex, the drugs given to protect patients from infection must be evaluated as potential players in the treatment itself, not as pharmacological bystanders. The next experiments, in animal models and eventually in patients, will determine whether this laboratory warning becomes a clinical rule.

Subject of Research: Interaction between the antibiotic cefazolin and the chemotherapeutic drug irinotecan in glioblastoma and neuroblastoma cells

Article Title: Antibiotic-chemotherapy interaction in brain tumors: cefazolin reduces chemotherapeutic efficacy of irinotecan in glioblastoma and neuroblastoma cells

Article References: Şişli, İ., Yüce, M., & Albayrak, E. (2026). Antibiotic-chemotherapy interaction in brain tumors: cefazolin reduces chemotherapeutic efficacy of irinotecan in glioblastoma and neuroblastoma cells. Medical Oncology, 43(11), Article 302. https://doi.org/10.1007/s12032-026-03403-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03403-6

Keywords: cefazolin, irinotecan, glioblastoma, neuroblastoma, antibiotics, chemotherapy, drug interactions, cell cycle, flow cytometry, MTT assay, topoisomerase inhibitor, cancer pharmacology